Abstract
Hypoxia has been reported to regulate both stem cell maintenance and differentiation. Wnt signaling is also a key regulator in stem cells. The recent discovery of functional cross-regulation between the Wnt pathway and HIF- 1α/HIF-2α signaling further highlights the complexity of the role of hypoxia in the regulation of stem cells. In this report we reveal that human CML cell lines treated under hypoxic conditions increase the percentage of leukemia stem/initiating-like cells, as judged by surface marker expression, colony forming ability and quiescence. We demonstrate that differential usage of the Kat3 coactivators, CREBBP/Creb Binding Protein (CBP) and EP300 (p300) by catenin, with increased CBP/catenin signaling at the expense of p300/catenin signaling, is mechanistically correlated with the increase in the leukemia stem/initiating-like population. A specific small molecule inhibitor of CBP/catenin dependent transcription, ICG-001, can reverse these effects further demonstrating the critical involvement of CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions.
Keywords: CBP, CML, ICG-001, hypoxia, leukemia initiating cell, Wnt/catenin inhibitor.
Current Molecular Pharmacology
Title:Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription
Volume: 6
Author(s): Aiko Kida and Michael Kahn
Affiliation:
Keywords: CBP, CML, ICG-001, hypoxia, leukemia initiating cell, Wnt/catenin inhibitor.
Abstract: Hypoxia has been reported to regulate both stem cell maintenance and differentiation. Wnt signaling is also a key regulator in stem cells. The recent discovery of functional cross-regulation between the Wnt pathway and HIF- 1α/HIF-2α signaling further highlights the complexity of the role of hypoxia in the regulation of stem cells. In this report we reveal that human CML cell lines treated under hypoxic conditions increase the percentage of leukemia stem/initiating-like cells, as judged by surface marker expression, colony forming ability and quiescence. We demonstrate that differential usage of the Kat3 coactivators, CREBBP/Creb Binding Protein (CBP) and EP300 (p300) by catenin, with increased CBP/catenin signaling at the expense of p300/catenin signaling, is mechanistically correlated with the increase in the leukemia stem/initiating-like population. A specific small molecule inhibitor of CBP/catenin dependent transcription, ICG-001, can reverse these effects further demonstrating the critical involvement of CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions.
Export Options
About this article
Cite this article as:
Kida Aiko and Kahn Michael, Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription, Current Molecular Pharmacology 2013; 6 (3) . https://dx.doi.org/10.2174/1874467207666140219121219
DOI https://dx.doi.org/10.2174/1874467207666140219121219 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued) Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Chemoinformatics in Multi-target Drug Discovery for Anti-cancer Therapy: In Silico Design of Potent and Versatile Anti-brain Tumor Agents
Anti-Cancer Agents in Medicinal Chemistry Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Antibody-Onconase Conjugates: Cytotoxicity and Intracellular Routing
Current Pharmaceutical Biotechnology Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients
Current Clinical Pharmacology Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Polyisoprenylation Potentiates the Inhibition of Polyisoprenylated Methylated Protein Methyl Esterase and the Cell Degenerative Effects of Sulfonyl Fluorides
Current Cancer Drug Targets Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Advanced Intraoperative MR Imaging
Current Medical Imaging